Comparison of the Effectiveness of Platelet-Rich Plasma (PRP) Therapy with Steroid Therapy in Improving the Clinical Symptoms of Patients with Rheumatoid Arthritis.

Evaluation of the efficacy of Platelet-Rich Plasma (PRP) therapy in Rheumatoid arthritis Patients.

A clinical trial with a control group, parallel-group randomized trial with blinded outcome assessment, phase 3 on 40 patients.

The study will be conducted at the Autoimmune Diseases Research Center of Shiraz University of Medical Sciences. Drug prescription and therapeutic intervention will be done in the rheumatology department of Hafez Hospital.

Inclusion criteria: Patients with rheumatoid arthritis. Exclusion criteria: patients who are being treated or suffering from other autoimmune diseases.

The control group is Rheumatoid arthritis patients treated with standard steroid medicine. The experimental group is Rheumatoid arthritis Patients who are treated with platelet-rich plasma.

1. Determination of Erythrocyte Sedimentation Rate, C-Reactive Protein, Anti Citrullinated peptide Antibody, Antinuclear Antibodies, and Rheumatoid Factor serum levels in patients before and after Platelet-Rich Plasma therapy. 2. Evaluation of Interleukin 1 beta synovial fluid levels in patients before and after Platelet-Rich Plasma therapy. 3. Evaluation of radiological examination in Rheumatoid Arthritis patients before and after Platelet-Rich Plasma therapy. 4. Evaluation of synovial fluid cell counts in Rheumatoid Arthritis patients before and after Platelet-Rich Plasma therapy. 5. Calculation of Disease Activity Score-28 in Rheumatoid Arthritis patients before and after Platelet-Rich Plasma therapy.

Simple randomization methods: The method of simple random assignment is that odd numbers are given to the intervention group (platelet-rich plasma prescription) and even numbers are given to the control group (common treatment with triamcinolone prescription). Then, according to the number of the studied sample, the relevant numbers are extracted from the table of random numbers or using a computer, each number is written on a card and placed in an envelope, and the envelopes are sealed, and the patient's number is written on each envelope. And the first patient who is registered in the study and enters the study will be given the envelope related to patient number 1, patient number 2 will be given envelope number 2 and so on, this work will continue until the end of the study sample. The person who prepares the envelopes will be different from the person who registers the patients and provides the envelopes to the patients. Considering that the treatment allocation of patients is done by the doctor, in order to prevent the influence of the doctor's opinion, the registration of the patients and their allocation in each of the groups will be done by the doctor's assistant and someone other than the doctor.

In our study, the investigator, the physician evaluating the treatment, those responsible for data collection, and those evaluating the outcome are blinded. In this study, in order to avoid applying the personal opinion of the doctor evaluating the course of treatment, he/she will be unaware of the type of treatment received in each of the research subjects, and it is important to note that during the stages of the research, due to the patient's contact with the doctor, blinding will not disappear. Those responsible for data collection should be unaware of the type of treatment received by the people participating in the research. Those who evaluate the results are chosen outside the treatment team so that even if the researcher knows the type of intervention assigned to the participants in the research, their knowledge does not affect the data analysis.

The participants' data is part of their privacy.